EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate.
Bekkenk
Marcel W
MW
Vermeer
Maarten H
MH
Meijer
Chris J L M
CJ
Jansen
Patty M
PM
Middeldorp
Jaap M
JM
Stevens
Servi J C
SJ
Willemze
Rein
R
D000368:Aged; D001402:B-Lymphocytes / Q000473:pathology; D001549:Benzamides; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D000068877:Imatinib Mesylate; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000473:pathology; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000209:etiology* / Q000473:pathology
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate